tbuckley/cabot-search huggingface dataset:
A three‐stage design for allergen immunotherapy trials
Authors: Xinyu Tang, Ronald L. Rabin, Lihan K. Yan
Journal: Allergy (2021)

Clinical trials of allergen immunotherapy (AIT) may require up to 5 years to complete. These lengthy trials may be complicated by high and potentially differential dropouts, especially among participants who perceive that they are receiving placebo. We propose a three-stage design in which the placebo group in Stage 1 crosses over to receive active treatment in Stage 2. In Stage 3, AIT is discontinued to determine whether benefit is maintained post-treatment. We apply inferential statistics to support the three-stage design for clinical trials to determine clinical efficacy, treatment response over time, and sustained response to AIT.The proposed framework constitutes a series of hypothesis tests for comparing treatment responses at the end of each stage. A simulation study was performed to illustrate the statistical properties under varying statistical missing mechanisms and effect sizes.The statistical properties in terms of bias and statistical power were consistent with what are expected from conventional analyses. Specifically, the extent of bias depended on the missing mechanism and magnitude. The statistical powers were largely driven by effect and sample sizes as well as prespecified success margins. As an illustration, assuming relative treatment differences of 25% and stagewise dropout rate of 15%, a sample size of 200 per group may achieve 93% power to demonstrate a treatment effect and 60% power to demonstrate a maintained response post-treatment.Inferential statistics support our proposed study design for evaluating benefits of AIT over time and inform clinical understanding and decisions.
1022P Frequency of PD1-negative and PD-1-positive ILCs in breast cancer patients depending on PD-L1 status
Authors: V.V. Alifanov, A. Buzenkova, N.O. Popova, O.E. Savelieva, L.A. Tashireva, V.M. Perelmuter
Journal: Annals of Oncology (2021)
1271P Molecular driver mutations in never-smokers with lung adenocarcinoma
Authors: P.C. Mack, M. Klein, K. Ayers, A. Uzilov, X. Zhou, D. Corrigan, M. Dietz, M. Fink, S. Guin, N.S. Kip, M. Rossi, W. Oh, F. Hantash, S. Newman, E.E. Schadt, R. Chen, F. Hirsch
Journal: Annals of Oncology (2021)
602P Prevalence of castration-resistant prostate cancer (CRPC) of unknown metastatic status in the real-world setting: The AfrODiTA study
Authors: M. Rodrigo-Aliaga, J.L. Álvarez-Ossorio, A. Rodríguez-Alonso, Á. García García-Porrero, A. Quesada-García, J. Muñoz del Toro, A. Rodríguez-Antolín
Journal: Annals of Oncology (2021)
515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Authors: J.S. Lim, R. Sundar, A. Wong, W-P. Yong, R. Soo, C.E. Chee, S.C. Lee, B.C. Goh, R. Dent, S. d/o Nathan Jeraj, L. Kwok, G. Schiavon, N. Kaliaperumal, A. Foxley, J.E. Connolly, D.S. Tan
Journal: Annals of Oncology (2021)
Toward a New Era for the Indian Health System
Authors: Jessica Leston, Brigg Reilley
Journal: New England Journal of Medicine (2021)

Interview with Jessica Leston on challenges facing the system that provides health care to American Indians and Alaska Natives. (10:11)Download The Indian Health System is poorly resourced and understaffed. Now is a promising time to reflect on big solutions for fostering a transformative, rather than transactional, relationship between the federal government and tribal nations.
295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)
Authors: L. Bortot, D. Basile, G. Targato, D. Zara, L. Palmero, M. Alberti, S. Buriolla, C. Noto, G. Pascoletti, E. Poletto, C. Andreetta, S. Russo, M. Mansutti, L. Gerratana, M. Bonotto, G. Fasola, F. Puglisi, A.M.M. Minisini
Journal: Annals of Oncology (2021)
1282P Biology of immune resistance in oncogenic driven advanced non-small cell lung cancer (aNSCLC)
Authors: M. Aldea, W. Zrafi, F-X. Danlos, C. Parisi, D. Drubay, F. Blanc-Durand, I. Padioleau, C. Nicotra, A. Gazzah, P. Lavaud, P. Abdayem, S. Nikolaev, D. Planchard, A. Italiano, F. Barlesi, J-C. Soria, L. Friboulet, A. Marabelle, D. Gautheret, B. Besse
Journal: Annals of Oncology (2021)
Bio-clickable mussel-inspired peptides improve titanium-based material osseointegration synergistically with immunopolarization-regulation
Authors: Jie Sun, Yingkang Huang, Huan Zhao, Junjie Niu, Xuwei Ling, Can Zhu, Lin Wang, Huilin Yang, Zhilu Yang, Guoqing Pan, Qin Shi
Journal: Bioactive Materials (2021)

Upon the osteoporotic condition, sluggish osteogenesis, excessive bone resorption, and chronic inflammation make the osseointegration of bioinert titanium (Ti) implants with surrounding bone tissues difficult, often lead to prosthesis loosening, bone collapse, and implant failure. In this study, we firstly designed clickable mussel-inspired peptides (DOPA-N3) and grafted them onto the surfaces of Ti materials through robust catechol-TiO2 coordinative interactions. Then, two dibenzylcyclooctyne (DBCO)-capped bioactive peptides RGD and BMP-2 bioactive domain (BMP-2) were clicked onto the DOPA-N3-coated Ti material surfaces via bio-orthogonal reaction. We characterized the surface morphology and biocompatibility of the Ti substrates and optimized the osteogenic capacity of Ti surfaces through adjusting the ideal ratios of BMP-2/RGD at 3:1. In vitro, the dual-functionalized Ti substrates exhibited excellent promotion on adhesion and osteogenesis of mesenchymal stem cells (MSCs), and conspicuous immunopolarization-regulation to shift macrophages to alternative (M2) phenotypes and inhibit inflammation, as well as enhancement of osseointegration and mechanical stability in osteoporotic rats. In summary, our biomimetic surface modification strategy by bio-orthogonal reaction provided a convenient and feasible method to resolve the bioinertia and clinical complications of Ti-based implants, which was conducive to the long-term success of Ti implants, especially in the osteoporotic or inflammatory conditions.
Atypical opioid receptors: unconventional biology and therapeutic opportunities
Authors: Christie B. Palmer, Max Meyrath, Meritxell Canals, Evi Kostenis, Andy Chevigné, Martyna Szpakowska
Journal: Pharmacology & Therapeutics (2021)

Endogenous opioid peptides and prescription opioid drugs modulate pain, anxiety and stress by activating four opioid receptors, namely μ (mu, MOP), δ (delta, DOP), κ (kappa, KOP) and the nociceptin/orphanin FQ receptor (NOP). Interestingly, several other receptors are also activated by endogenous opioid peptides and influence opioid-driven signaling and biology. However, they do not meet the criteria to be recognized as classical opioid receptors, as they are phylogenetically distant from them and are insensitive to classical non-selective opioid receptor antagonists (e.g. naloxone). Nevertheless, accumulating reports suggest that these receptors may be interesting alternative targets, especially for the development of safer analgesics. Five of these opioid peptide-binding receptors belong to the family of G protein-coupled receptors (GPCRs)-two are members of the Mas-related G protein-coupled receptor X family (MrgX1, MrgX2), two of the bradykinin receptor family (B1, B2), and one is an atypical chemokine receptor (ACKR3). Additionally, the ion channel N-methyl-d-aspartate receptors (NMDARs) are also activated by opioid peptides. In this review, we recapitulate the implication of these alternative receptors in opioid-related disorders and discuss their unconventional biology, with members displaying signaling to scavenging properties. We provide an overview of their established and emerging roles and pharmacology in the context of pain management, as well as their clinical relevance as alternative targets to overcome the hurdles of chronic opioid use. Given the involvement of these receptors in a wide variety of functions, including inflammation, chemotaxis, anaphylaxis or synaptic transmission and plasticity, we also discuss the challenges associated with the modulation of both their canonical and opioid-driven signaling.
167P Role of the multi-gene panel testing for detection of pathogenic variants in patients with hereditary bilateral breast cancer
Authors: C. Filorizzo, D. Fanale, L. Incorvaia, N. Barraco, M. Bono, C. Brando, V. Calò, D. Cancelliere, A. Cucinella, A. Dimino, A. Fiorino, L. Magrin, E. Pedone, A. Perez, A. Pivetti, S. Sammataro, R. Sciacchitano, G. Vaccaro, V. Bazan, A. Russo
Journal: Annals of Oncology (2021)
748P Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Authors: M. Romeo Marin, M. Gil-Martin, L. Gaba Garcia, C. Fina, Á. Taus, P. Murata, M. Masvidal, A. Martinez, J. Fernández-Plana, Y. García, C. Pérez, S. Cros Costa, V. Rodriguez, M. Zanui, S. Catot, A. Plaja, I. Teruel, B. Pardo Búrdalo, M-P. Barretina-Ginesta, A.M. Esteve
Journal: Annals of Oncology (2021)
1832P Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review
Authors: A. Olivares Hernandez, R.A. Escala Cornejo, I. Toribio García, L. Figuero Pérez, R. Vidal Tocino, J.P. Miramontes González, G. Martín García, R. Seijas Tamayo, J.J. Cruz-Hernández, C.A. Rodriguez Sanchez
Journal: Annals of Oncology (2021)
705P Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC)
Authors: L. Bloudek, Z. Hepp, C. McKay, B. Devine, C. Derleth, J. Lill, E. Lenero, P. Wright, S.D. Ramsey, S.D. Sullivan
Journal: Annals of Oncology (2021)
1203P The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Authors: E.N. Imyanitov, E. Preobrazhenskaya, A. Romanko, A. Martianov, N. Mitiushkina, V. Tiurin
Journal: Annals of Oncology (2021)
797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158
Authors: D. O'Malley, G.M. Bariani, P.A. Cassier, A. Marabelle, A.R. Hansen, A. De Jesus Acosta, W.H. Miller, T. Safra, A. Italiano, L. Mileshkin, M. Amonkar, L. Xu, F. Jin, K. Norwood, M. Maio
Journal: Annals of Oncology (2021)
Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
Authors: Deborah E. Malden, Katia J. Bruxvoort, Hung Fu Tseng, Bradley Ackerson, Soon Kyu Choi, Ana Florea, Julia Tubert, Harpreet Takhar, Michael Aragones, Vennis Hong, Carla A. Talarico, John M. McLaughlin, Lei Qian, Sara Y. Tartof
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Data from observational studies demonstrate that variants of SARS-CoV-2, the virus that causes COVID-19, have evolved rapidly across many countries (1,2). The SARS-CoV-2 B.1.617.2 (Delta) variant of concern is more transmissible than previously identified variants,* and as of September 2021, is the predominant variant in the United States.† Studies characterizing the distribution and severity of illness caused by SARS-CoV-2 variants, particularly the Delta variant, are limited in the United States (3), and are subject to limitations related to study setting, specimen collection, study population, or study period (4-7). This study used whole genome sequencing (WGS) data on SARS-CoV-2-positive specimens collected across Kaiser Permanente Southern California (KPSC), a large integrated health care system, to describe the distribution and risk of hospitalization associated with SARS-CoV-2 variants during March 4-July 21, 2021, by patient vaccination status. Among 13,039 SARS-CoV-2-positive specimens identified from KPSC patients during this period, 6,798 (52%) were sequenced and included in this report. Of these, 5,994 (88%) were collected from unvaccinated persons, 648 (10%) from fully vaccinated persons, and 156 (2%) from partially vaccinated persons. Among all sequenced specimens, the weekly percentage of B.1.1.7 (Alpha) variant infections increased from 20% to 67% during March 4-May 19, 2021. During April 15-July 21, 2021, the weekly percentage of Delta variant infections increased from 0% to 95%. During March 4-July 21, 2021, the weekly percentage of variants was similar among fully vaccinated and unvaccinated persons, but the Delta variant was more commonly identified among vaccinated persons then unvaccinated persons overall, relative to other variants. The Delta variant was more prevalent among younger persons, with the highest percentage (55%) identified among persons aged 18-44 years. Infections attributed to the Delta variant were also more commonly identified among non-Hispanic Black persons, relative to other variants. These findings reinforce the importance of continued monitoring of SARS-CoV-2 variants and implementing multiple COVID-19 prevention strategies, particularly during the current period in which Delta is the predominant variant circulating in the United States.
In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE)
Authors: Pu-Sheng Wei, Yi-Jou Chen, Shyr-Yi Lin, Kuo-Hsiang Chuang, Ming-Thau Sheu, Hsiu-O Ho
Journal: Biomaterials (2021)
1555TiP A phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS): The PULSAR trial
Authors: A. Indini, A. Tourlaki, F. Barbin, L. Brambilla, D. Gambini, E. Berti, F. Grossi
Journal: Annals of Oncology (2021)
1716P Do proton pump inhibitors affect the survival outcomes and safety in colorectal cancer patients treated with regorafenib? A single center and real-life experience
Authors: E. Yekeduz, N. Özyurt, E.B. Köksoy, I. Akbıyık, E. Kalacı, Y. Ürün, G. Utkan
Journal: Annals of Oncology (2021)
980P Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
Authors: N. Yamamoto, H. Ida, T. Shimizu, Y. Nakamura, M. Nishino, S. Yazaki, Y. Katsuya, J. Sato, T. Koyama, S. Iwasa, K. Sudo, S. Kondo, K. Yonemori, S. Shiono, T. Suzuki, T. Takase, S. Takashima, K. Yamaguchi, T. Semba, K. Shitara
Journal: Annals of Oncology (2021)
76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
Authors: A. Oaknin, L. Gilbert, A. Tinker, J. Brown, C. Mathews, J.Z. Press, R. Sabatier, D. O'Malley, V. Samouelian, V. Boni, L. Duska, S. Ghamande, P. Ghatage, R. Kristeleit, C. Leath, X. Han, S. Kumar, T. Duan, E. Im, B. Pothuri
Journal: Annals of Oncology (2021)
Abstract 15783: Neo-Chord Construction on Fusion Cusp for Bicupid Aortic Valve Repair in Combination With Aortic Root Repair
Authors: Kikuko Obase, Takashi Miura, Junichiro Eishi, Hiroko Taguchi, Taku Inoue, Akihiko Tanigawa, Tessho Kitamura, Shun Nakaji, Ichiro Matsumaru, Kiyoyuki Eishi
Journal: Circulation (2019)

Introduction: Fundamental surgical treatment for severe aortic regurgitation (AR) in bicuspid aortic valve (BAV) consists of root reshaping and leaflet repair. Leaflet plication is widely accepted ...
Re: Hyperparathyroidism Due to Concurrent Parathyroid Carcinoma and Parathyroid Adenoma
Authors: Hongyan Yin, Hongcheng Shi
Journal: Clinical Nuclear Medicine (2021)

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China [email protected] Conflicts of interest and sources of funding: Supported by Hongyan Yin was sponsored by a Young Scholar Grant from the National Natural Science Foundation of China (81501500).
Prophages encode phage-defense systems with cognate self-immunity
Authors: Siân V. Owen, Nicolas Wenner, Charles L. Dulberger, Ella V. Rodwell, Arthur Bowers-Barnard, Natalia Quinones-Olvera, Daniel J. Rigden, Eric J. Rubin, Ethan C. Garner, Michael Baym, Jay C.D. Hinton
Journal: Cell Host & Microbe (2021)

Temperate phages are pervasive in bacterial genomes, existing as vertically inherited islands termed prophages. Prophages are vulnerable to predation of their host bacterium by exogenous phages. Here, we identify BstA, a family of prophage-encoded phage-defense proteins in diverse Gram-negative bacteria. BstA localizes to sites of exogenous phage DNA replication and mediates abortive infection, suppressing the competing phage epidemic. During lytic replication, the BstA-encoding prophage is not itself inhibited by BstA due to self-immunity conferred by the anti-BstA (aba) element, a short stretch of DNA within the bstA locus. Inhibition of phage replication by distinct BstA proteins from Salmonella, Klebsiella, and Escherichia prophages is generally interchangeable, but each possesses a cognate aba element. The specificity of the aba element ensures that immunity is exclusive to the replicating prophage, preventing exploitation by variant BstA-encoding phages. The BstA protein allows prophages to defend host cells against exogenous phage attack without sacrificing the ability to replicate lytically.
408P Characteristics of patients with colorectal cancer who underwent surgery for liver metastases and pattern of relapse
Authors: M. Alva Bianchi, J. Soto Alsar, N. Gutiérrez Alonso, M. Bringas Beranek, R. Martin Lozano, C. López Jimenez, A. Gutiérrez Ortiz de la Tabla, R. Jiménez Rodríguez, M.I. Aparicio Salcedo, M. Arregui Valles, M.I. Gallego Gallego, G. García González, L. Ortega Morán, M. Blanco, G. Torres Pérez-Solero, A. Calvo, A. Muñoz Martín, P. García-Alfonso
Journal: Annals of Oncology (2021)
195P A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients
Authors: A. Adam Artigues, M.Á. Beltrán, J.A. Carbonell-Asins, S. Zuñiga, S. Moragón, M.T.M. Martinez, C. Hernando Melia, None O. Burgués, F. Rojo Todo, J. Albanell Mestres, A. Lluch-Hernandez, B. Bermejo, P. Eroles, J.M. Cejalvo
Journal: Annals of Oncology (2021)
440P Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients
Authors: E. Hafliger, A. Boccaccino, R. El-Khoury, A. Perret, F. Pietrantonio, L. Pilla, T. Lecomte, M. Scartozzi, E. Soularue, L. Salvatore, V. Bourgeois, M. Salati, J.N. Vaillant, C. Gallois, S. Lonardi, C. Cremolini, J. Taieb
Journal: Annals of Oncology (2021)
840P Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Authors: Y-K. Shi, Y. Qin, W. Zhang, X. Wang, H. Liu, A. Zang, L. Yang, D. Lin, F. Li, H. Zhu, R. Zhao
Journal: Annals of Oncology (2021)
Music and dance are two parallel routes for creating social cohesion
Authors: Steven Brown
Journal: Behavioral and Brain Sciences (2021)

Savage et al. do an excellent job of making the case for social bonding in general, but do a less good job of distinguishing the manners by which dance and music achieve this. It is important to see dance and music as two parallel and interactive mechanisms that employ the "group body" and "group voice," respectively, in engendering social cohesion.
746P Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France
Authors: M. Rodrigues, F. Joly, I.L. Ray-Coquard, H. Costaz, J-M. Classe, A. Floquet, T. De La Motte Rouge, P-E. Colombo, M. Provansal Gross, E. Leblanc, C. Pomel, F. Marchal, E. Barranger, A.M. Savoye, C. Guillemet, T. Petit, P. Pautier, R. Rouzier, C. Courtinard, L. Gladieff
Journal: Annals of Oncology (2021)
329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer
Authors: S. Loi, A. Schneeweiss, E. Song, M. Harries, M. De Laurentiis, Y. Li, C. Wiese, R. Poppe, L.A. Emens
Journal: Annals of Oncology (2021)
Vonoprazan-containing therapy has an <i>H pylori</i> eradication rate &gt;90% and increases eradication vs. standard triple therapy
Authors: Rashid N. Lui, Francis K.L. Chan
Journal: Annals of Internal Medicine (2021)

Source Citation Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology. 2021;161:495-507. 33839101
Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency
Authors: Man-Di Wang, Da-Yong Hou, Gan-Tian Lv, Ru-Xiang Li, Xing-Jie Hu, Zhi-Jia Wang, Ni-Yuan Zhang, Li Yi, Wan-Hai Xu, Hao Wang
Journal: Biomaterials (2021)
1493P An evaluation of the psychological impact of early phase clinical trials in cancer patients
Authors: P. Jittla, D. Graham, C. Zhou, J. Halliwell, S. O'Reilly, S. Aruketty, A. Azizi, T. Germetaki, J. Lowe, M. Little, G. Punnett, P. McMahon, L. Benson, L. Carter, M.G. Krebs, F. Thistlethwaite, J. Yorke, N. Cook
Journal: Annals of Oncology (2021)
203P Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer
Authors: M.E. Cazzaniga, N. Martinez Jañez, B.D. Kukielka-Budny, M. Ulanska, H. Bourgeois, M. Muñoz Mateu, S. Morales Murillo, J. Bayo, L. Cortesi, T. Pinter, M. Palacova, N. Cherciu, E. Petru, J. Ettl, C. De Almeida, R. Raymond, G.R. Villanova, C. Ta Thanh Minh, A.C.F. Rodrigues, G. Freyer
Journal: Annals of Oncology (2021)
Bonding system in nonhuman primates and biological roots of musicality
Authors: Yuko Hattori
Journal: Behavioral and Brain Sciences (2021)

Abstract Comparative studies of primates indicate that humans have evolved unique motivations and cognitive skills for sharing emotions, experiences, and collaborative actions. Given the characteristics of music, the music and social bonding (MSB) hypothesis by Savage et al. fits this view. Within a cross-species approach, predispositions not observed in current communication system may contribute to a better understanding of the biological roots of human musicality.
1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality
Authors: M.M. De Meza, R. Ismail, W.A.M. Blokx, C.U. Blank, A.J.M. Van den Eertwegh, M. Aarts, A.C.J. van Akkooi, F. Van den Berkmortel, M. Boers-Sonderen, E. Kapiteijn, J.W.B. de Groot, J.B.A.G. Haanen, G.A. Hospers, D. Piersma, R.S. van Rijn, A.A.M. Van der Veldt, G. Vreugdenhil, H.M. Westgeest, K. Suijkerbuijk, M.W.J.M. Wouters
Journal: Annals of Oncology (2021)
1249P Pharmacokinetic and dose finding study of osimertinib in patients with impaired renal function and low body weight
Authors: T. Hase, Y. Fujiwara, R.A. Makihara, N. Hashimoto, Y. Tsubata, T. Okuno, T. Naito, T. Takahashi, H. Kobayashi, Y. Shinno, T. Ikeda, K. Goto, Y. Hosomi, K. Watanabe, S. Kitazono, N. Sakiyama, Y. Makino, N. Yamamoto
Journal: Annals of Oncology (2021)
484P CD300c blockade promotes anti-cancer immunity and synergizes with immune checkpoint inhibitor in colon cancer
Authors: H. Shin, W.S. Lee, S.I. Lee, J.H. Kim, J-H. Yeom, B. Kang, J-E. Seo, J. Cheon, J-G. Jung, J-W. Jeon, C. Kim, H.J. Chon
Journal: Annals of Oncology (2021)
431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC)
Authors: R.A. Adams, D.J. Fisher, J. Graham, J. Seligmann, M. Seymour, R.S. Kaplan, E. Yates, S. Richman, P. Quirke, R. Butler, E. Brown, F. Collinson, S. Falk, R. Wilson, L.C. Brown, T. Maughan
Journal: Annals of Oncology (2021)